Fig. 6.

HPLC analysis of the striatal levels of DA (a, e), DOPAC (b, f), and HVA (c, g) 4 weeks after injection of AAV9 vectors in control groups and groups injected with AAV9-α-syn WT (a–d) or AAV9-α-syn A53T (e–h). The striatal turnover of DA calculated by the DOPAC/DA ratio is also shown (d, h). Measurements show significant reductions in DA and metabolites in lesioned rats relative to controls (saline and empty vectors), which were significantly improved by treatment with candesartan or telmisartan. Data are means ± SEM. ^*p < 0.05 relative to the saline-injected group; ^#p < 0.05 relative to the AAV9-Ф-injected group; ^&p < 0.05 relative to the group injected with AAV9 expressing human WT α-syn (a, b) or expressing human A53T mutated α-syn (e–h). One-way ANOVA followed by Holm–Sidak post hoc test. Abbreviations: α-syn A53T = A53T mutated alpha-synuclein; α-syn WT = wild-type alpha-synuclein; ANOVA = analysis of variance; CAND = candesartan; DA = dopamine; DOPAC = 3,4-dihydroxyphenylacetic acid; HVA = homovanilic acid; SEM = standard error of the mean; TELM = telmisartan; Ф = empty-null